An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Phase of Trial: Phase I/II
Latest Information Update: 18 Aug 2015
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Trastuzumab
- Indications Advanced breast cancer; Brain metastases; Glioma; Malignant melanoma; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors BBB Therapeutics
- 10 Jun 2017 Biomarkers information updated
- 21 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2014 Planned End Date changed from 1 Mar 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History